Crescent BiopharmaFRA:C68 10 PB Ratio is 2.59 as of Jul. 04, 2026, which is 1% below its 10-year median of 2.62. GuruFocus rates FRA:C68 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,228 Biotechnology companies, Crescent Biopharma ranks better than 54.72% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Crescent Biopharma PB Ratio Related Terms
Crescent Biopharma PB Ratio Historical Data
* Premium members only.
The historical data trend for Crescent Biopharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Crescent Biopharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crescent Biopharma PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crescent Biopharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Crescent Biopharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Crescent Biopharma (FRA:C68) has a PB Ratio of 2.59 as of Jul. 04, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Crescent Biopharma and its competitors. This is near median its historical median of 2.62. Over the past decade, Crescent Biopharma's PB Ratio has ranged from 1.37 to 3.80. According to the industry distribution chart, Crescent Biopharma ranks #556 out of 1228 companies in the Biotechnology industry, placing it in the top 45.3%.
Is Crescent Biopharma's PB Ratio too high?
Crescent Biopharma's current PB Ratio of 2.59 is near median its 10-year median of 2.62. Over the past 10 years, this metric has ranged from a low of 1.37 to a high of 3.80. The Biotechnology industry median PB Ratio is 2.97. Crescent Biopharma's value of 2.59 is 12.8% below this industry median. Based on the distribution chart, Crescent Biopharma ranks #556 out of 1228 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Crescent Biopharma has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's PB Ratio compare to KYTX and ZURA?
According to the Biotechnology industry distribution chart, Crescent Biopharma ranks #556 out of 1228 companies for PB Ratio. This puts Crescent Biopharma in the upper half of its industry. The industry median PB Ratio is 2.97. Crescent Biopharma's value of 2.59 is 12.8% below this benchmark. Historically, Crescent Biopharma's own PB Ratio has ranged from 1.37 to 3.80 over the past decade. While the company's 10-year median is 2.62 vs. the industry median of 2.97, Crescent Biopharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.97, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crescent Biopharma's current PB Ratio of 2.59 is 12.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Crescent Biopharma and its competitors. For the Biotechnology industry, the median PB Ratio is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crescent Biopharma's current PB Ratio is 2.59, which is near median its own 10-year median of 2.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (FRA:C68) has a current PB Ratio of 2.59. The current PB Ratio is 2.59, which is near median its 10-year median of 2.62 and 12.8% below the Biotechnology industry median of 2.97. Crescent Biopharma's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Crescent Biopharma (FRA:C68), the current PB Ratio is 2.59 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
10GF Score
Get the complete analysis for FRA:C68
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:C68 has been successfully added to your 